Heritage Announces the Launch of Acyclovir Capsules

East Brunswick, NJ, May 14, 2018. Heritage Pharmaceuticals Inc. (“Heritage”) announced the immediate availability of Acyclovir 200mg Capsules. This launch adds to Heritage’s robust portfolio of generic oral solid products. Acyclovir is the AB rated generic equivalent to the antiviral drug Zovirax®. It is indicated for the treatment of herpes zoster, genital herpes and chickenpox. According to IMS data for the twelve-months ended May 2018, the U.S. market for Acyclovir Capsules is approximately $6.9 million.

Download Press Release